share_log

WORK Medical Technology Group Announces The Underwriter Of Its IPO Partially Exercised Its Over-Allotment Option, Bringing The Total Ordinary Shares Sold To 2,091,942 And Gross Proceeds To ~$8.37M

WORK Medical Technology Group Announces The Underwriter Of Its IPO Partially Exercised Its Over-Allotment Option, Bringing The Total Ordinary Shares Sold To 2,091,942 And Gross Proceeds To ~$8.37M

WORk医疗科技集团宣布其IPO的包销商部分行使了超额配售选择权,使得总普通股销售量达到2,091,942股,总收益约为8.37百万美元
Benzinga ·  08/29 16:41

WORK Medical Technology Group LTD (NASDAQ:WOK) (the "Company"), a supplier of medical devices in China, today announced the underwriter of its initial public offering (the "Offering") has partially exercised its over-allotment option to purchase an additional 91,942 ordinary shares at the public offering price of US$4.00 per share. After giving effect to the partial exercise of the over-allotment option, the total number of ordinary shares sold by the Company in the public offering increased to 2,091,942 ordinary shares and the gross proceeds increased to approximately $8.37 million, before deducting underwriting discounts and offering expenses payable by the Company. The option closing date was August 29, 2024. The ordinary shares began trading on the Nasdaq Capital Market on August 23, 2024, under the ticker symbol "WOK."

WORk医疗科技集团有限公司(纳斯达克:WOK)(以下简称“公司”)是中国的医疗设备供应商,今天宣布首次公开发行(以下简称“发行”)的承销商已部分行使超额配售权,以以每股4.00美元的发行价购买额外的91,942股普通股。在行使超额配售权的部分后,公司在公开发行中的普通股总数增至2,091,942股,总募集资金增至大约83.7万美元,扣除公司支付的承销折扣和发行费用。选项截止日期为2024年8月29日。普通股于2024年8月23日在纳斯达克资本市场上市,股票代码为“WOk”。

Proceeds from the Offering will be used for (i) upgrading production equipment and increasing production capacity, (ii) developing masks, other medical consumables and medical devices, (iii) product marketing, (iv) patent purchases, and (v) working capital and other general corporate purposes.

发行所得将用于(i)升级生产设备和扩增生产能力,(ii)开发口罩、其他医疗耗材和医疗设备,(iii)产品营销,(iv)购买专利,(v)营运资金和其他一般企业用途。

The Offering was conducted on a "firm commitment" basis. Kingswood Capital Partners, LLC ("Kingswood") acted as the sole book running manager for the Offering. Hunter Taubman Fischer & Li LLC acted as U.S. counsel to the Company, and Ortoli Rosenstadt LLP acted as U.S. counsel to Kingswood in connection with the Offering.

发行是以“坚定承诺”方式进行的。Kingswood Capital Partners, LLC(简称“Kingswood”)担任发行的唯一主承销商。Hunter Taubman Fischer & Li LLC担任公司的美国法律顾问,Ortoli Rosenstadt LLP担任Kingswood的美国法律顾问。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发